To date, over $28 million has been raised by the Foundation to provide practical and tangible help for cancer patients receiving treatment in the NSW public hospital service.
The NELUNE Foundation is committed to providing world-class facilities and services to cancer patients, regardless of their social or financial circumstances – 'Helping Patients Fight Cancer With Dignity'.
The NELUNE Foundation was co-founded by two friends in 2001, Nelune Rajapakse and Anna Guillan AM. With the support of the community, these two friends have been united in their quest to make a difference to the lives of those who have been diagnosed with cancer. Nelune is a cancer survivor who knows and understands the difficulties of being diagnosed with this illness.
In 2017, the NELUNE Foundation funded the establishment of the Rebecca Wilson Fellowship in Cancer Research in partnership with the Garvan Institute of Medical Research with a commitment of $1 million dollars over five years. This fellowship was awarded to a young demaile scientist at Garvan, and is a lasting legacy to sports journalist and long term NELUNE Foundation supporter, the late Rebecca Wilson.
The inaugural recipient of the Rebecca Wilson Fellowship in Cancer Research is Dr Christine Chaffer, a gifted breast cancer researcher.
Dr Chaffer's research at Garvan will aim to determine the role and mechanism of breast cancer cell plasticity (the ability fo a cancer cell to adapt and change its composition) in disease development and metastasis to assist develop personalised therapies that will, ultimately, improve breast cancer survival rates and provide a pathway to a cure.
07 FEB 2017 - Our Bec is still changing lives (The Daily Telegraph)
07 FEB 2017 - Legacy Pioneers Research (Advertiser Adelaide)
08 FEB 2017 - Dr Christine Chaffer remembers Rebecca Wilson (video - The Daily Edition)
08 FEB 2017 - Rebecca Wilson honoured (video - The Daily Edition)
The NELUNE Foundation raised $6m to help fund the construction of the Nelune Comprehensive Cancer Centre, a world-class centre of cancer care excellence situated in the Bright Building at the Prince of Wales Hospital Campus Sydney.
Opened in February 2017, the Nelune Comprehensive Cancer Centre has brought together, under one roof, cancer services from Prince of Wales Hospital, the Royal Hospital for Women and Sydney Children's Hospital.
It is a cancer facility for all citizens - irrespective of age or socioeconomic status. Uniquely, the Nelune Comprehensive Cancer Centre houses the Sydney Youth Cancer Unit, a state cancer genetics service and the internationally renowned gynecological cancer service from the Royal Hospital for Women.
The new Centre creates a physical environment that promotes recovery and ensures the best available treatment is delivered by teams of health professionals committed to public hospital medicine. Research-led excellence in cancer care will draw on the 400 cancer research scientists in the Lowy Cancer Centre at the nearby University of NSW. These researchers are working on new ways to diagnose and treat a range of cancers including brain cancer.
The Nelune Centre is located on the ground floor of the $100 million Kinghorn Cancer Centre (370 Victoria Street Darlinghurst Sydney) and is a world-class centre of excellence in patient cancer care treatment. It is a joint initiative between the Garvan Institute of Medical Research and St Vincent’s & Mater Health Sydney.
It is a place of hope and dignity which provides fully integrated care to cancer patients, regardless of their personal or financial circumstances. Patients from all over New South Wales are referred to the Centre upon diagnosis and have access to world-class multi-disciplinary services including Oncologists, Clinical Psychologists, Researchers, Cancer Care Co-ordination, chemotherapy treatments in outdoor garden surrounds, transportation and other patient support services.
The NELUNE Foundation is funding Garvan's Molecular Screening and Therapeutic trial (MoST). Via the Nelune Centre, MoST gives patients with rare cancers or who have exhausted all other treatment options, access to a highly personalised and innovative clinical trial.
Through MoST, each participant's genome (their entire DNA) is compared with the genome of their tumour to identify the underlying cause of their cancer and to target treatment accordingly.
The demand for this service is currently far higher than the funding available and the Foundation is seeking to ensure that no patient who needs this service will go without.
We would like to thank the below businesses for their unwavering support and generosity.
If you would like to find out more about becoming a corporate sponsor of the NELUNE Foundation please get in touch.